tbuckley/cabot-search huggingface dataset:
Healing by design: The influence of an artistic design on the well being of cancer patients—A 10 years follow up
Authors: H. Samonigg, E. Andritsch, G. Dietmaier, T. Bauernhofer, H. Andritsch, S. Zloklikovits, A. K. Kasparek, H. Stoeger, R. Schaberl-Moser, F. Ploner
Journal: Journal of Clinical Oncology (2006)

18615 Background: The style of the surrounding in which cancer patients, who experience physical as well as high psychological distress are treated, can help them to acquire a sense of security, to reduce their anxiety and depression. Inspired by this model the famous artist F. Hundertwasser created the redesign of the oncological ward with the aim to generate an atmosphere of security by utilizing bright, warm and vivid colours, light and plants. The aim of this study was to investigate in a prospective manner whether the artistic redesign have an influence on the welfare of cancer patients using standardized questionnaires pre and immediately post reconstruction and in a follow up 10 years later. Methods: A total of 261 patients were interviewed (93 before the redesign, 81 immediately and 87 ten years after redesign) to assess the influence of depression (Zerssen Depression Scale, PD-S) quality of life (Spitzer Index)and perceptions of the ward design (semi-structured interview) on wellbeing (Zerrsen Mood Scale, Bf-S). Results: A factor analysis of the semi-structured interview yielded four factors assessed with a MANOVA showing that patients interviewed after redesign reported more positive effects of the ward design (F 2;227 = 484.274; p &lt; 0.001). In addition, they were more content with treatment and medical care (F 2;227 = 20.103; p &lt; 0.001), more positive in their emotions and thoughts regarding illness (F 2;227 = 8.600; p = 0.003) and placed greater importance on the fixtures (F 2;227 = 6.067; p = 0.003) than the patients interviewed before the redesign. In a regression analysis depression, the “impact of ward design”, quality of life, gender, “emotions and thoughts regarding illness”, age and education predicted wellbeing with an “R” of 0.0469 (p &lt; 0.05). Conclusions: The results provide important aspects for the discussion if the physical surroundings in which cancer patients are treated serve as a potentially positive factor in the “healing process”. No significant financial relationships to disclose.
<italic>Brief Communication:</italic> Spontaneous Lymphoma Associated With <italic>Herpesvirus saimiri</italic> in Owl Monkeys<xref ref-type="fn" rid="fn2">2</xref>
Authors: H Rabin, R H Neubauer, G R Pearson, J L Cicmanec, W C Wallen, W F Loeb, M G Valerio
Journal: JNCI Journal of the National Cancer Institute (1975)

Two cases of lymphoma and one case of lymphoproliferative disease were found in a group of 7 owl monkeys imported into our colony as a single group. Herpesvirus saimiri (HVS) was isolated from the tumor cells of 1 lymphoma by cocultivation and from kidney cell cultures from the monkey with Iymphoproliferative disease. Antibody to HVS was found in serum samples from 2 monkeys positive for HVS but not in the sera from the 4 clinically normal monkeys. Antibody to Epstein-Barr virus-infected cells was also found in the serum from the animal with Iymphoma.
Indocyanine Green Liposomes for Diagnosis and Therapeutic Monitoring of Cerebral Malaria
Authors: Emma Portnoy, Natalia Vakruk, Ameer Bishara, Miriam Shmuel, Shlomo Magdassi, Jacob Golenser, Sara Eyal
Journal: Theranostics (2015)

Cerebral malaria (CM) is a major cause of death of Plasmodium falciparum infection. Misdiagnosis of CM often leads to treatment delay and mortality. Conventional brain imaging technologies are rarely applicable in endemic areas. Here we address the unmet need for a simple, non-invasive imaging methodology for early diagnosis of CM. This study presents the diagnostic and therapeutic monitoring using liposomes containing the FDA-approved fluorescent dye indocyanine green (ICG) in a CM murine model. Increased emission intensity of liposomal ICG was demonstrated in comparison with free ICG. The Liposomal ICG's emission was greater in the brains of the infected mice compared to naïve mice and drug treated mice (where CM was prevented). Histological analyses suggest that the accumulation of liposomal ICG in the cerebral vasculature is due to extensive uptake mediated by activated phagocytes. Overall, liposomal ICG offers a valuable diagnostic tool and a biomarker for effectiveness of CM treatment, as well as other diseases that involve inflammation and blood vessel occlusion.
Randomized multicenter phase III trial comparing neoadjuvant RT-Capox and RT-Cap in patients (pts) with locally advanced rectal cancer: Preliminary safety results of the ACCORD 12/0405 PRODIGE-2
Authors: J. Gérard, D. Azria, S. Gourgou-Bourgade, I. Martel-Lafay, C. Hennequin, P. Etienne, G. De Laroche, L. Mineur, V. Vendrely, C. Montoto-Grillot
Journal: Journal of Clinical Oncology (2008)

4089 Background: Both the FFCD 9203 [J Clin Oncol 2006;24:4620–5] and the EORTC 22921 [NEJM 2006;355:1114–23] trials showed superiority of neoadjuvant chemoradiation (CT-RT) to radiotherapy (RT) alone in terms of pathological complete response (pCR) and local control in locally advanced rectal cancers (LARC). The ACCORD 12/0405 PRODIGE-2 trial was initiated to optimize this neoadjuvant approach. Methods: Pts with T3 or resectable T4 or distal T2, N0–1-2 non metastatic rectal adenocarcinoma were randomized to either arm A: concurrent RT 45Gy/25f/5w + capecitabine (800mg/m²/bid) (RT-Cap) or arm B: concurrent RT 50Gy/25f/5w + capecitabine (800mg/m²/bid) + oxaliplatin 50mg/m²/w (RT-Capox). Randomization was stratified by center, tumor site, and stage. Total mesorectal excision (TME) was scheduled 6 weeks after the end of CT-RT. Adjuvant chemotherapy was optional. 590 pts were needed to show an increase in the pCR rate from 11% (arm A) to 20% (arm B) with a two-sided 5% alpha and 85% power. Secondary endpoints included toxicity, conservative surgery, local relapse and survival. This report presents preliminary safety data from the first 150 pts with complete data 60 days after surgery. Results: Between 11/2005 and 12/2007, a total of 409 pts were randomized (204 and 205 in arm A and B, respectively) in 54 centers. Patient characteristics were well balanced at baseline: male 67%, median age 61 years (range : 25–80), 61% low rectum, 87% T3 stage. No toxic death was observed. Compliance to surgery appeared satisfactory. Conclusions: The safety profile of the RT-Cap arm (A) was as expected. Toxicities in RT-Capox arm (B) were acceptable and allowed continuation of accrual to the study. Results on the primary endpoint should be available in 2009. Updated and detailed safety results will be shown at the meeting. Arm A:45Gy+Cap Arm B:50 Gy+Capox N° pts n=78 n=72 Grade 3 all toxicities 5% 19% Grade 4 all toxicities 0% 4% Grade 3/4 diarrhea 3% 16% Grade 2 sensory neuropathy 0% 6% Surgery performed 99% 99% Postoperative death (within 60 days) 0 0 No significant financial relationships to disclose.
Sports injuries and illnesses during the 2015 Winter European Youth Olympic Festival
Authors: G Ruedl, M Schnitzer, W Kirschner, R Spiegel, H Platzgummer, M Kopp, M Burtscher, E Pocecco
Journal: British Journal of Sports Medicine (2016)

The prevention of injury and illness remains an important issue among young elite athletes. Systematic surveillance of injuries and illnesses during multi-sport events might provide a valuable basis to develop preventive measures, focusing especially on adequate information for youth athletes.To analyse the frequencies and characteristics of injuries and illnesses during the 2015 Winter European Youth Olympic Festival (W-EYOF).All National Olympic Committees were asked to report daily the occurrence or non-occurrence of newly sustained injuries and illnesses on a standardised reporting form.Among the 899 registered athletes (37% female) with a mean age of 17.1±0.8 years, a total of 38 injuries and 34 illnesses during the 5 competition days of the W-EYOF were reported, resulting in an incidence of 42.3 injuries and 37.8 illnesses per 1000 athletes, respectively. Injury frequency was highest in snowboard cross (11%), Nordic combined (9%), alpine skiing (6%), and ice hockey (6%), taking into account the respective number of registered athletes. In snowboard cross, females showed a significant higher injury frequency compared to males (22% vs 4%, p=0.033). The lower back (16%), the pelvis (13%), the knee (11%), and the face (11%) were the most common injury locations. About 58% of injuries occurred in competition and about 42% in training. In total, 42% of injuries resulted in an absence of training or competition. The prevalence of illness was highest in figure skating (10%) and Nordic combined (9%), and the respiratory system was affected most often (53%).Four per cent of the athletes suffered from an injury and 4% from illnesses during the 2015 W-EYOF, which is about twofold lower compared to the first Winter Youth Olympic Games in 2012.
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Authors: G P Sutton, F B Stehman, L H Einhorn, L M Roth, J A Blessing, C E Ehrlich
Journal: Journal of Clinical Oncology (1989)

Fifty-six patients were randomly assigned to receive either one-day cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy (PAC-I) or five-day PAC (PAC-V) for advanced epithelial ovarian carcinoma. Follow-up has been 120+ months or to death. Ninety-one percent had either suboptimal stage III or stage IV disease and 55% had grade 2 or 3 lesions. Two patients died of toxicity and were free of disease at autopsy. A third patient died of congestive heart failure with no disease at 103 months. Additionally, eight patients had a negative second-look laparotomy, and three (37.5%) are alive with no evidence of disease (NED) 133 to 144 months after diagnosis. Five patients (62.5%) died of disease 2 to 123 months after negative second-look. Patients with optimal stage III disease had a longer median progression-free interval (PFI) and survival (33.3 and 44.5 months, respectively) than those with suboptimal or stage IV disease (16.4 and 22.5 months, respectively), and the difference in median PFI is significant (P less than .02). Patients with ascites at diagnosis had a shorter median PFI and survival (14.7 and 18 months) than those without ascites (30.0 and 33.0 months). Both differences were significant (PFI, P less than .04; survival, P = .005). PAC produces response rates that are superior to those obtained historically with single-agent alkylating therapy. Late recurrences after negative second-look laparotomy suggest that 5-year survival data may be inadequate in ovarian carcinoma.
Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre–metastatic Niche
Authors: Amber Jin Giles, Caitlin Marie Reid, Justin DeWayne Evans, Meera Murgai, Yorleny Vicioso, Steven Lorenz Highfill, Miki Kasai, Linda Vahdat, Crystal Lee Mackall, David Lyden, Leonard Wexler, Rosandra Natasha Kaplan
Journal: Cancer Research (2016)

Abstract Metastatic tumors have been shown to establish microenvironments in distant tissues that are permissive to disseminated tumor cells. Hematopoietic cells contribute to this microenvironment, yet the precise initiating events responsible for establishing the pre-metastatic niche remain unclear. Here, we tracked the developmental fate of hematopoietic stem and progenitor cells (HSPC) in tumor-bearing mice. We show that a distant primary tumor drives the expansion of HSPCs within the bone marrow and their mobilization to the bloodstream. Treatment of purified HSPCs cultured ex vivo with tumor-conditioned media induced their proliferation as well as their differentiation into immunosuppressive myeloid cells. We furthered tracked purified HSPCs in vivo and found they differentiated into myeloid-derived suppressor cells in early metastatic sites of tumor-bearing mice. The number of CD11b+Ly6g+ cells in metastatic sites was significantly increased by HSPC mobilization and decreased if tumor-mediated mobilization was inhibited. Moreover, pharmacologic mobilization of HSPCs increased metastasis, whereas depletion of Gr1+ cells abrogated the metastasis-promoting effects of HSPC mobilization. Finally, we detected elevated levels of HSPCs in the circulation of newly diagnosed cancer patients, which correlated with increased risk for metastatic progression. Taken together, our results highlight bone marrow activation as one of the earliest steps of the metastatic process and identify circulating HSPCs as potential clinical indicators of metastatic niche formation. Cancer Res; 76(6); 1335–47. ©2015 AACR.
Author’s reply to Dubicka and colleagues and Stone
Authors: Peter C Gøtzsche
Journal: BMJ (2016)

Dubicka and colleagues say that we are likely to harm young people when we point out that antidepressants increase the risk of suicide.1 2 They consider it harmful that some young people will not start taking antidepressants because they think that these drugs do more harm than good. What is harmful is when these authors and other psychiatrists claim that these drugs protect against suicide despite the solid evidence we have to the contrary and the clear warnings from drug agencies. Dubicka and colleagues say that “It is well established that the undertreatment of depression in children and young people is linked to suicide” and refer to an observational study. There are many such studies, but they are all flawed.3

These authors say that our statement that antidepressants doubled the risk of suicide in children and adolescents is incorrect, and they argue that there is a “hugely important difference” between suicides and suicidal behaviour. There isn’t. A suicide starts with a thought about suicide, which leads to preparations for suicide, a suicide attempt, and suicide. It should surprise no one that the risk factors for serious suicide attempts are similar to those for suicide.4 5

Their other arguments are also invalid. There is no need …
Pharmacodynamic study of soluble FAS (sFAS) and FASL (sFASL), in patients (pts) with advanced colorectal cancer (ACRC) after irinotecan and cetuximab treatment in third-line therapy: Results of HCB-05–01 trial
Authors: X. Garcia-Albeniz, C. Pericay, V. Alonso, P. Escudero, C. Fernandez-Martos, J. Augé, R. Gallego, M. Tosca, P. Gascón, J. Maurel
Journal: Journal of Clinical Oncology (2008)

22046 Background: No predictive markers of cetuximab efficacy in ACRC, have been validated prospectively fulfilling REMARK criteria. We have previously observed in ACRC pre-treated pts a decrement of sFAS (sFAS/sFASL) ratio (Nadal et al, Clin Cancer Res., 2005) and in a pharmacodynamic study an increment of sFAS ratio between 24–72 h, after first-line therapy (Carcereny et al Proc. ASCOGI, 2006). We hypothesize that changes of sFAS ratio could be an early biological predictor marker to cetuximab-irinotecan efficacy in third-line therapy. Methods: Pts with ACRC and progressive disease (PD) to oxaliplatin and irinotecan, with WHO PS 0–2 were eligible on a multicenter study. Pts received cetuximab (400 mg/m2 initial dose then 250 mg/m2 (w) plus irinotecan 180 mg/m2 q 2w. Serum analysis of sFAS and sFASL were done by ELISA basally and at 48 hours. Spiral computed tomography were done basally, every 2 months until six months, and every 3 months thereafter until PD. Response was assessed q 4 cycles. Primary end point was progression free survival (PFS). 76 pts were needed assuming α and β errors of 0.05 and 0.2 respectively to detect ≥40% of pts without PD at 4 months in the group of sFAS ratio increment above the median (A) compared with ≤10% of pts with PD in the group with sFAS ratio below the median (B). Results: 93 pts were recruited between May 2005 and July 2007. Median age was 63 (range 38–84) years. PFS was 3.3 (95% CI 1.9–4.8) months in the group B and 3.1 (95% CI 2.5–3.6) months (p=0.86) in the group A. Univariate analysis identified the following variables associated with PFS: PS 1 (HR 1.67, 95% CI 1.01–2.76), PS 2 (HR 2.92, 95% CI 1.16–7.34), LDH (0.02% increase of risk, 95% CI 0.002–0.05) and CEA (0.02% increase of risk, 95% CI 0.002–0.04). Multivariate analysis identified LDH as a prognostic factor for survival. Conclusions: Variation of sFAS ratio after treatment with cetuximab and irinotecan in ACRC, is not predictor of PFS. sFAS ratio ≤ 0.03 sFAS ratio > 0.03 p PFS (95% CI) 3.3 (1.9-4.8) 3.1 (2.5-3.6) 0.864 OS (95% CI) 9.66 (5.65-13.67) 7.66 (6.58-8.73) 0.192 Response rate (%) 6 (15) 5 (11.6) 0.641 No significant financial relationships to disclose.
Longitudinal Brain Changes Associated with Prophylactic Cranial Irradiation in Lung Cancer
Authors: Marta Simó, Lucía Vaquero, Pablo Ripollés, Ane Gurtubay-Antolin, Josep Jové, Arturo Navarro, Felipe Cardenal, Jordi Bruna, Antoni Rodríguez-Fornells
Journal: Journal of Thoracic Oncology (2016)
Persistence of occult metastatic cells in bone marrow after adjuvant systemic therapy predicts relapse in localized breast cancer
Authors: B. Bermejo, A. Lluch, I. Benet, J. M. Sastre, J. V. Ferrer, T. Garcia, L. Chumbes, P. Martinez, J. Garcia-Conde
Journal: Journal of Clinical Oncology (2004)

657 Background: The presence of isolated tumor cells (ITC) in bone marrow (BM) in breast cancer patients has been evaluated in numerous studies. The majority of these studies have found correlation between the presence of ITC in BM and increased risk of relapse. In this study we assessed the association between the presence of BM and established prognostic factors in localizated breast cancer patients, and analyzed the influence of adjuvant therapies on the remove of these cells as a prognostic factor. Methods: BM aspirates from 296 patients with primary breast cancer with stages I-III (112 node negative, and 184 node positive), treated with adjuvant systemic chemotherapy (CT) with antracyclines, were evaluated. All patients underwent BM aspirate at diagnosis. In addition, 202 of these patients also underwent a second BM aspirate after CT. Carcinoma cells were detected using a standardized immunoassay with monoclonal antibody A45-B/B3 directed against cytokeratin. Detection of >= 2 tumor cells was scored as positive. Results: At diagnosis, 82 of 296 (28%) patients presented ITC in BM. The presence of ITC in BM did no correlate with standard prognostic variables such as lymph node status, tumor size, histological grade, hormonal receptor levels and expression of HER-2 neu. After a median follow up of 35 months (6–130), 53 patients (18%) relapsed (10 node negative, and 43 node positive). In the global group, the presence of ITC in BM at diagnosis showed a tendency to predict worse disease-free survival (DFS) and overall survival (OS). In the lymph node-positive group, 62% of patient showing ITC in the second BM aspirate after CT relapsed, whereas 21% of those with both negative BM aspirates presented relapse. The presence of ITC in the second BM aspirate was associated with inferior DFS (P=0,01) and OS (p=0,002). Conclusions: Our analytical approach allows the identification of micrometastatic BM disease in localized breast cancer patients that would be usually undetected using conventional methods. The persistence of occult metastatic cells in BM after adjuvant systemic therapy predicts relapse in localized breast cancer. No significant financial relationships to disclose.
Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intentsity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study
Authors: Pritesh R. Patel, Annie L. Oh, Matthew Koshy, Bulent Aydogan, Nadim Mahmud, David Peace, John G. Quigley, Santosh L. Saraf, Enzo DeMasi, Ralph R Weichselbaum, Damiano Rondelli
Journal: Blood (2013)
A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia
Authors: J. Garcia, R. V. Boccia, C. Graham, K. Kumor, W. Polvino
Journal: Journal of Clinical Oncology (2007)

9133 Background: Cancer cachexia is closely correlated with poor outcome and poor survival. RC is an oral ghrelin mimetic with orexigenic and anabolic activity. Methods: A phase II trial enrolled 81 patients with cancer, performance scores of 0–2, and weight loss of 5% or more within 6 months prior to enrollment at 17 sites in the US. Patients were randomized to treatment with two placebo (PL) or two 25 mg RC capsules taken once daily for 12 weeks. Outcome measures included lean body mass (LBM), total body mass (TBM) by DEXA (central reading), scale weight, handgrip strength (HS) and QOL measures. Biochemical markers included IGF-1 and IGFBP-3. In the per protocol analysis (32 RC, 28 PL) more than 20 cancer types were represented; the most common were lung (n=13) and colorectal cancer (n=15). The two treatment groups were balanced at baseline except for (RC vs PL, respectively): gender (66 % male vs 57 %), TBM (60.9 kg vs 65.3 kg), and HS (53.8 kg vs 56.6 kg). The analyses (repeated measures ANOVA without imputation) included all available data from the patients. Results: TBM and LBM (primary endpoint at 8 wks) were significantly increased vs. PL at wks 4 and 8 and at wks 4, respectively. The magnitude of the increase vs. baseline was stable from wk 4 through wk 12 during RC treatment for both TBM and LBM. HS was increased at significantly at wk 8. IGF-1 and IGFBP-3 significantly increased at wks 4, 8, and 12. No significant differences were found on the QOL or scale weight measures. RC was well tolerated. Patients having any AEs were 96% vs 87% and SAEs were 32% and 26% for RC and PL, respectively. The percent of patients and types of AEs were similar; possible exceptions included cardiac events and infections (11% vs 3% and 30% vs 42%, RC vs PL, respectively). Conclusions: In this randomized, double-blind, placebo-controlled trial, RC treatment led to improvements in LBM, TBM and HS. RC-1291 is a promising potential therapeutic agent for the treatment of cancer cachexia. No significant financial relationships to disclose.
Douglas Noel Golding
Authors: H. Baker
Journal: BMJ (2015)

Douglas Noel Golding was born in Dublin, the eldest of the three sons of a local general practitioner. With his mother and brothers he was evacuated to Bermuda during the second world war, while his father served in the Royal Navy. He qualified in medicine from Trinity College Dublin. After an internship in Canada, he settled in England and embarked on a training in rheumatology, initially at the teaching hospital in Newcastle upon Tyne and then at …